Table 1. Summary of published outcomes... | American Society of Hematology

Table 1.

Summary of published outcomes for infants treated on collaborative group protocols over the past 25 years according to KMT2A status

Study	Year	KMT2A-rearranged			KMT2A-germline			Reference
Study	Year	Number of infants	5-year EFS, %	5-year OS, %	Number of infants	5-year EFS, %	5-year OS, %	Reference
CCG-1953	1996-2000	79	33.6	—	36	60.3	—	³⁹
COG P9407	2001-2006	100	35.5	—	35	69.7	—	⁴⁰
COG AALL0631	2008-2014	146	34	41	64	87.3	93.6	^4,6
Interfant-99	1999-2005	311^a	35.9^a,b	43.2^a,b	79	74.5^b	83.4^b	^5,41
Interfant-06	2006-2016	476	36.4^b	48.0^b	167	73.9^b	87.2^b	^5,41
JILSG MLL96	1995-1998	80	38.6	50.8	22	95.5	95.5	⁴²
JILSG MLL98	1998-2001	80	38.6	50.8	22	95.5	95.5	⁴²
JPLSG MLL03	2004-2009	62	43.2^c	67.2^c	—	—	—	⁴³
JPLSG MLL-10	2011-2015	75	66.2	82.0	15	93.3	100	⁴⁴

Study	Year	KMT2A-rearranged			KMT2A-germline			Reference
Study	Year	Number of infants	5-year EFS, %	5-year OS, %	Number of infants	5-year EFS, %	5-year OS, %	Reference
CCG-1953	1996-2000	79	33.6	—	36	60.3	—	³⁹
COG P9407	2001-2006	100	35.5	—	35	69.7	—	⁴⁰
COG AALL0631	2008-2014	146	34	41	64	87.3	93.6	^4,6
Interfant-99	1999-2005	311^a	35.9^a,b	43.2^a,b	79	74.5^b	83.4^b	^5,41
Interfant-06	2006-2016	476	36.4^b	48.0^b	167	73.9^b	87.2^b	^5,41
JILSG MLL96	1995-1998	80	38.6	50.8	22	95.5	95.5	⁴²
JILSG MLL98	1998-2001	80	38.6	50.8	22	95.5	95.5	⁴²
JPLSG MLL03	2004-2009	62	43.2^c	67.2^c	—	—	—	⁴³
JPLSG MLL-10	2011-2015	75	66.2	82.0	15	93.3	100	⁴⁴

CCG, Children's Cancer Group; JILSG, Japan Infant Leukemia Study Group; JPLSG, Japanese Pediatric Leukemia/Lymphoma Study Group; OS, overall survival; —, not reported.

Data obtained following personal communication with the Interfant Trial Data Center.

Six-year EFS and OS.

Four-year EFS and OS.

View Large

This Feature Is Available To Subscribers Only